Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

This study is testing a new targeted drug called SY-5007 for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has a specific genetic change called a RET fusion — a mutation that drives cancer growth. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic NSCLC confirmed by biopsy - Your tumor has a RET fusion gene change (confirmed by genetic test) - You have not received any prior treatment for advanced/metastatic NSCLC - You have at least one measurable tumor lesion - You are in reasonably good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to the brain and is untreated - You have an active autoimmune disease requiring ongoing treatment - You have significant heart, liver, or kidney problems - You have had a prior organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.